Mr. Gergen joined Halozyme in September 2016 in a new role reporting to the CEO as Senior Vice President and Chief Operating Officer. He is responsible for business development, including the management of Halozyme’s proprietary ENHANZE™ platform collaborations and overseeing the global product teams responsible for planning the development and commercialization of Halozyme’s oncology pipeline, including clinical operations and clinical collaborations.
He brings more than 20 years of executive management and business development experience to Halozyme, with an extensive background in the biotechnology sector. Prior to joining Halozyme, he most recently served as Executive Vice President and Chief Operating Officer for Mirati Therapeutics, an oncology biotech company, responsible for the strategy, corporate development, finance, investor relations, human resources, information technology and legal functions where he executed multiple successful partnerships, collaborations and licensing agreements.
Before Mirati, he was Senior Vice President of Corporate Development for Amylin Pharmaceuticals, leading business development and alliances. Earlier in his career, he held senior management roles at Cardionet and Advanced Tissue Sciences, as well as the large group purchasing organization, Premier, and medical device pioneer, Medtronic.
He earned his B.A. in Business Administration from Minot State University in North Dakota and J.D. from the University of Minnesota Law School.